What elitek does

ELITEK (rasburicase) is a Sanofi-marketed biopharmaceutical product indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to cause Tumor Lysis Syndrome (TLS) and subsequent hyperuricemia. The active ingredient, rasburicase, is a recombinant DNA-derived urate oxidase enzyme that catalytically degrades uric acid into allantoin, a more soluble and renally excretable metabolite. In a Phase 3 trial, prophylactic ELITEK maintained plasma uric acid at ≤7.5 mg/dL in 87% of patients versus 66% for allopurinol between days 3 and 7 (P=0.001). The product has been FDA-approved for over 20 years, is indicated for only a single course of treatment, and carries a boxed warning for hypersensitivity reactions, hemolysis (including G6PD-deficiency contraindication), methemoglobinemia, and interference with uric acid laboratory measurements.

The technology platform is a single-asset, single-mechanism biologic with no disclosed pipeline extensions. Commercially, ELITEK is marketed to US oncologists, hematologists, and pediatric oncologists through Sanofi's pharmaceutical sales force and the Sanofi Pro Campus HCP portal, which provides clinical data, dosing guidance, mechanism-of-action content, and patient-risk-factor resources. Distribution is handled through specialty pharmacies, pharmaceutical wholesalers, and direct purchase channels for healthcare facilities, with cold-chain handling requirements due to the biologic nature of the product.

ELITEK generates revenue through prescription product sales to hospitals, oncology clinics, and specialty pharmacies that dispense the drug to patients undergoing chemotherapy. Pricing is not publicly disclosed; procurement occurs through Sanofi's account relationships and specialty pharmacy partners. The product is positioned within Sanofi's broader specialty biologics portfolio alongside Thyrogen, ALPROLIX, and other rare disease and oncology assets that are managed through the Genzyme-era commercial infrastructure Sanofi acquired.

Name

elitek

Legal name

Sanofi

Website

https://elitekpro.com

Company type

Public

Operating status

Operating

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

akta.pro primary industry

Onconephrology (Kidney Care in Cancer Patients) (HLAKAHAM)

akta.pro secondary industries

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH), Rare Renal & Nephrology Disorder Therapies (HLAIAIAI), Nephrology & Urology Pharmaceuticals (HLAIAAAM)

Keywords

• Tumor lysis syndrome treatment
• Recombinant urate oxidase
• Hyperuricemia management
• Oncology biologic drug
• Uric acid reduction

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Pharmaceutical product sales: ELITEK is a prescription biopharmaceutical product sold to healthcare facilities and through specialty pharmacy channels. Revenue is generated through product sales to hospitals, clinics, and specialty pharmacies that dispense the drug to patients undergoing anticancer therapy.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels1 record

Core offering

ELITEK (rasburicase) is a prescription recombinant urate oxidase enzyme biologic administered as an IV infusion for the initial management of plasma uric acid levels in pediatric and adult patients with hematologic malignancies and solid tumors who are receiving anticancer therapy expected to cause tumor lysis. It is sold by Sanofi through specialty pharmacies, wholesalers, and direct institutional purchasing to hospitals, clinics, and oncology treatment centers.

Product overview

ELITEK (rasburicase) is a pharmaceutical product for the management of tumor lysis syndrome. The company operates a multi-product pharmaceutical portfolio including therapeutic biologics, vaccines, and small molecule medications across therapeutic areas including oncology (ELITEK), hematology (ALPROLIX for hemophilia B), cardiovascular (AVAPRO/AVALIDE for hypertension), vaccines (MenQuadfi for meningococcal disease, NUVAXOVID for COVID-19), endocrinology (Thyrogen for thyroid cancer), and pediatrics/infectious disease (Beyfortus for RSV prevention in infants). These products are distributed through the Sanofi Campus HCP portal.

Differentiator

Problem solved

Functional benefit

Brands

• Sanofi Campus: Healthcare professional portal providing product information and resources
• ThyrogenONE
• HemAssist

Products and services

• ELITEK (rasburicase) for injection

Quantifiable outcome

• 87% of patients maintained normal uric acid levels (≤7.5 mg/dL) vs 66% for allopurinol (P=0.001) between 3-7 days after treatment initiation

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators2 records

Recent moves4 records

Expansion highlights2 records

Direct peers

• Horizon Therapeutics (Amgen): Markets Krystexxa (pegloticase), a recombinant uricase enzyme for chronic refractory gout, the closest mechanism analog to ELITEK's rasburicase. Both are parenteral biologics that enzymatically degrade uric acid and are positioned in specialty/rare disease channels, making Horizon the most directly comparable peer for ELITEK's recombinant urate oxidase platform.

Broad incumbents

• Takeda Pharmaceutical: Markets Uloric (febuxostat), an oral xanthine oxidase inhibitor for chronic hyperuricemia/gout, and has a broader oncology supportive care and rare disease portfolio. Comparable as a competitor in the broader uric acid-lowering therapeutic space and as a specialty/oncology pharma incumbent.
• Amgen: Major oncology supportive care franchise including Neulasta (pegfilgrastim) and Nplate (romiplostim); also the parent of Horizon Therapeutics/Krystexxa. Comparable as a large incumbent operating biologic supportive care products in similar hospital/specialty pharmacy channels.
• Alexion (AstraZeneca Rare Disease): Specialty rare disease unit of AstraZeneca commercializing biologics in ultra-rare and rare conditions. Comparable as a large specialty/rare disease commercial organization operating hospital-administered biologics with similar payer engagement and specialty distribution models.
• Bristol-Myers Squibb: Large oncology-focused pharma with a portfolio spanning hematology and solid tumor therapeutics; operates supportive care adjacencies in oncology. Comparable as a broad incumbent in oncology/hematology with similar institutional customer base.
• Astellas Pharma: Specialty/oncology pharma with hospital-administered biologics and rare disease products. Comparable as a large specialty pharma incumbent operating in oncology and rare disease supportive care.
• Pfizer: Large pharma with a substantial oncology supportive care portfolio and biosimilars business. Comparable as a broad incumbent that both competes in oncology supportive care biologics and represents a potential future biosimilar entrant into the recombinant urate oxidase space.

Emerging players

• Jazz Pharmaceuticals: Specialty biopharma focused on oncology and rare diseases with hospital-administered products. Comparable as a specialty pharma operating niche hospital-channel therapeutics with similar distribution and HCP-targeted commercial approaches.
• Swedish Orphan Biovitrum (Sobi): Specialty rare disease biopharma with a portfolio spanning hematology, oncology supportive care, and immunology. Comparable as a focused rare-disease/specialty pharma commercializing niche biologics through specialty pharmacy channels.
• Recordati Rare Diseases: Specialty pharma focused on rare diseases and oncology supportive care, with hospital-administered products. Comparable as a specialty distributor/marketer of niche hospital therapeutics operating in similar channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about elitek